Clinical studies in Type 2 diabetes mellitus have shown that the effects of metformin go beyond improving HbA(1c) and include reductions in cardiovascular endpoints. Metformin therapy has been widely used in the treatment of Type 2 diabetes for many years, yet the precise mode of action remains uncertain. It has recently been proposed that metformin-mediated stimulation of hepatic AMP-activated protein kinase (AMPK) underlies the hypoglycaemic effects of metformin. AMPK is a heterotrimeric enzyme that is expressed in many tissues and plays a central role in the regulation of energy homoeostasis. Furthermore, there is increasing evidence that AMPK is implicated in the pathophysiology of cardiovascular and metabolic diseases. The generation of more specific and potent activators of AMPK, however, could have additional metabolic and vascular benefits for patients with Type 2 diabetes.

Diabetes is a risk factor for cancer and specifically colorectal cancer. It is also associated with increased cancer mortality. Aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase 2 (Cox-2) inhibitors have been shown to decrease the incidence of colorectal cancer. This effect may be mediated by inhibiting prostaglandin synthesis. Long-term use of high-dose aspirin and NSAIDs is associated with significant gastrointestinal side effects. Unfortunately, the use of Cox-2 inhibitors is associated with an increased incidence of acute myocardial infarction and death from cardiovascular disease. The increased risk of cardiovascular disease in patients with diabetes results in the loss of the potential to use Cox-2 inhibitors for cancer chemoprophylaxis. Until a safer type of Cox-2 inhibitor is available, or low-dose aspirin is evaluated for chemoprophylaxis, a more intense screening programme for colorectal cancer may be appropriate for patients with diabetes, especially men. Healthcare professionals managing patients with diabetes should be aware of the increased risk of this type of cancer.

No abstract

Summary: Hypertensive disorders in pregnancy are common and can occur as a result of pre-existing hypertension or as new onset hypertension usually in the second half of pregnancy. In either situation there is potential for considerable perinatal and maternal morbidity and mortality. This review article aims to compare therapeutic options outlined in a selection of national guidelines and to look in more detail at the most commonly prescribed drugs -labetalol, methyldopa and nifedipine -with respect to their pharmacology and the evidence for their use in pregnancy. We will also consider the rationale for identifying and treating hypertension in pregnancy and the effect this can have on short-and long-term maternal and neonatal outcomes.

In this study we model the impact of introducing outpatient investigation of pulmonary thrombo-embolism (PTE) to the acute medical unit (AMU) using the Pulmonary Embolism Severity Index (PESI) decision rule. Specifically, we ask what proportion of patients requiring imaging could be investigated without admission, and how many bed-days this would save.  We obtained records for all medical patients who had imaging for PTE in a six-month period at a large teaching hospital with a 40-bedded AMU. The patients were categorized into suitability for outpatient investigation using a combination of the PESI rule and practical considerations. Three hundred and fifty-nine separate presentations were identified. From available records, 31 patients (9.2%, 95% confidence interval [CI] 6.6-12.8%) had no contraindications to outpatient management. These patients used a total of 79 bed-days in the six-month period, or 1.1% (95% CI 0.8-1.5%) of the maximum AMU bed occupancy. Around 10% of patients who require imaging for suspected PTE could be triaged to outpatient investigation using the PESI tool. Adopting this method to triage patients of ambulatory care, would have only a modest effect on acute medical bed occupancy, but remains a valid option for motivated patients in the low-risk category.